Press Latest Release http://www.csl.com.au CSL News Thu, 19 Jan 2017 09:00:00 -0500 FY2017 profit upgrade thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, particularly by immunoglobulins and specialty products in the most recent financial quarter, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.   http://www.csl.com.au/newsroom/FY2017-profit-upgrade.htm 1252903872987 Thu, 05 Jan 2017 00:00:00 -0500 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors thumbnail Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017.   http://www.csl.com.au/newsroom/Momenta-and-CSL-Announce-Collaboration-and-License-Agreement.htm 1252903829512